Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda San Francisco, a wholly owned subsidiary of Takeda Pharmaceutical Company of Osaka, Japan has appointed Mary Haak-Frendscho, as president and chief scientific officer.
Subscribe to our email newsletter
Dr Haak-Frendscho will be responsible for leading all activities at Takeda San Francisco including overall research and preclinical development, process development studies and operations for antibody therapeutics.
Most recently Dr Haak-Frendscho has served as chief science officer and vice president, preclinical research and development at Xoma. Dr Haak-Frendscho holds a doctorate in immunology from the University of Wisconsin-Madison and a Master’s in immunology from SUNY-Stony Brook. She received a Master of Liberal Arts from Washington University in St Louis, and a Bachelor of Science in zoology from the University of Michigan-Ann Arbor.
Shigenori Ohkawa, general manager, pharmaceutical research division, Takeda, said: “Dr Haak-Frendscho’s strong leadership skills and biotechnology experience will greatly contribute to the success of Takeda San Francisco.”